Knight Therapeutics Inc. Q1 2026 Earnings Recap

Knight Therapeutics shares jumped 15.7% following a record quarter driven by significantly higher revenues and adjusted EBITDA, with strong contributions from multiple portfolio acquisitions and new product launches exceeding expectations.

Key Takeaways

• Reported Q1 2026 revenues reached $148 million, up 68-69% year-over-year, fueled by the inclusion of Sumitomo and Paladin portfolios and growth in promoted products.
• Adjusted EBITDA surged 130% to $28 million, reflecting improved gross margins and despite a 44% increase in operating expenses to support the expanded portfolio.
• Adjusted gross margin improved slightly to 48% of revenues versus 47% a year ago, driven by higher sales volumes.
• The company executed four product launches during the quarter and advanced regulatory approvals in Brazil, Argentina, and Mexico.
• Net cash position strengthened to $69 million with ongoing debt repayments and a leverage ratio below 0.7x, underpinning financial flexibility.